Navigation Links
Study examines self-expanding plastic stents in the treatment of benign esophageal conditions
Date:1/25/2008

curred in more than 60 percent of all patients and of all stents placed, said the studys lead author Todd Baron, MD, FASGE, Mayo Clinic, Rochester. Stent migration rates were not influenced by dilation at the time of stent placement or stent size. Although stent placement typically resolved the patients symptoms initially, long-term resolution was infrequent in our study group. Only six percent of all procedures provided long-term resolution of symptoms after stents were removed.

Patients and Methods

This study was a retrospective review of cases of benign esophageal lesions in which a self-expanding nonmetallic Polyflex stent was placed at the Mayo Clinic, Rochester, from 2002 to 2006.

Thirty patients underwent at least one attempted SEPS placement. Nineteen patients were male and 11 were female, with an average age of 52.1 years. Twenty-two stents were placed in eight patients for benign strictures. Twenty-five stents were placed in 11 patients for anastomotic stricture after esophageal surgery. Twenty-two stents were placed in nine patients for esophageal fistulae or anastomotic leak. Fifteen stents were placed in five patients, and one stent placement was unsuccessful in one patient for radiation-induced strictures. A total of 83 stent placements were performed over the five-year period.

Overall, complications were minor and did not interfere with subsequent treatment. The most common initial complaints included chest pain, neck discomfort, and dysphagia (in 23 procedures) and nausea and vomiting (in eight procedures) and were managed with analgesic and antiemetic medications. Symptoms resolved within three days in most cases.

Results

Stents remained in place for an average of 53 days. Patients had symptomatic improvement initially in 77 of 83 stents placed (92.8 percent), three of 83 stents placed resulted in no symptom improvement, and three of 83 stents placed are awaiting follow up informat
'/>"/>

Contact: Anne Brownsey
abrownsey@asge.org
630-570-5635
American Society for Gastrointestinal Endoscopy
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Amalgam Fillings Dont Affect Childrens Brain Development, Says Study in ADA Journal
2. Amalgam fillings dont affect childrens brain development, says study in ADA Journal
3. Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds
4. From Research to Practice: Healthfitness, Eastman Chemical Company Case Study Demonstrates Real-World Health Gains and Productivity Savings
5. Study raises questions about diagnosis, medical treatment of ADHD
6. Another Study Links Western Diet to Heart, Health Risks
7. Nerites Receives NIH Grant to Study Novel Treatment for Preventing Dangerous Bacterial Infections on Urinary Stents and Catheters
8. New Kaiser Permanente study fortifies caffeines link to miscarriage
9. Kaiser Permanente study shows link between caffeine and miscarriage
10. Study looks at off-label use of biliary stents
11. Study: Brain connections strengthen during waking hours, weaken during sleep
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Americans United for Life Action Fights the Abortion Bailout by Supporting the Nelson-Hatch-Casey Amendment 2Health News:Patriot Scientific Corporation Announces New Director 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 3Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 2Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 3Health News:Lilly Announces the First 300-unit Vial of Insulin 2Health News:Lilly Announces the First 300-unit Vial of Insulin 3Health News:Lilly Announces the First 300-unit Vial of Insulin 4
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 1Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 2Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 3Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 60950 1Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 60950 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 1Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 3
Other Medicine Technology:CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 2CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 3CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 4CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 6CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 7CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 8CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 9CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 10Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7